E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Generalized Myasthenia gravis |
|
E.1.1.1 | Medical condition in easily understood language |
Myasthenia gravis (a neuromuscular disease) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028417 |
E.1.2 | Term | Myasthenia gravis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety and tolerability of M281 in patients with generalized myasthenia gravis (gMG) |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the long-term efficacy of M281, long term immunogenicity of M281 and long-term pharmacodynamic (PD) activity of M281 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Has completed the M281 POC study (ie, participated in the POC study without discontinuing study drug for reasons other than the need for rescue therapy as specified in the POC protocol, and completed the protocol-specified 8 weeks of follow-up after the last dose of study drug) and had no major eligibility deviations or other major protocol deviations in the POC study. If the patient received rescue therapy during the POC, the Medical Monitor should be consulted before the patient is enrolled in the OLE study. 2. Has sufficient venous access to allow drug administration by infusion and blood sampling as per this OLE protocol. 3. Is up to date on all age-appropriate vaccinations as per routine local medical guidelines. 4. Women of childbearing potential, defined as women physiologically capable of becoming pregnant, must have a negative urine pregnancy test predose on OLE study Day 1. Menopausal women who did not have elevated follicle-stimulating hormone (FSH) at the time of enrollment in the POC study must also have a negative urine pregnancy test predose on OLE study Day 1. 5. Women of childbearing potential (including menopausal women who did not have elevated FSH at the time of enrollment in the POC study) must agree to remain totally abstinent (ie, refrain from sexual intercourse during the study) or to consistently use a reliable and highly effective method of contraception (eg, condom plus diaphragm, condom plus spermicide, diaphragm plus spermicide, or intrauterine device or oral/injectable/implanted hormonal contraceptive used in combination with an additional barrier method) during the OLE study and for 30 days after the last M281 infusion. Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together. 6. Male patients must agree to remain totally abstinent (ie, refrain from sexual intercourse during the study) or to consistently use a reliable and highly effective method of contraception (eg, condom plus diaphragm, condom plus spermicide, diaphragm plus spermicide, or intrauterine device or oral/injectable/implanted hormonal contraceptive used in combination with an additional barrier method) to avoid pregnancy of the patient’s partner(s) during the OLE study and for 100 days following the last M281 infusion, unless the patient provides documentation of a vasectomy at least 6 months prior to OLE study enrollment. Male patients must also abstain from sperm donation during the OLE study and for 100 days following the last M281 infusion. Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together. 7. A patient using herbal, naturopathic, and traditional Chinese remedies and ayurvedic and nutritional supplements is eligible if the use of these medications is acceptable to the Investigator. These remedies should be at a stable dose and regimen using the same preparation since enrollment in the POC study. 8. Is able to understand and voluntarily provide written informed consent to participate in the long-term OLE study and comply with all study procedures for duration of the OLE study. |
|
E.4 | Principal exclusion criteria |
1. Has Myasthenia Gravis Foundation of America (MGFA) Class IVb or V disease. 2. Met any of the study drug stopping criteria in the POC study or discontinued study drug in the POC study for any reason (eg, adverse event [AE]) other than the need for rescue therapy as specified in the POC protocol. (If the patient received rescue therapy during the POC, the Medical Monitor should be consulted before the patient is enrolled in the OLE study.) 3. Has current suicidal ideation evidenced by a "yes" response to questions 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) administered predose on OLE study Day 1. 4. Currently has a serious or clinically significant infection (eg, pneumonia, biliary tract infection, diverticulitis, Clostridium difficile infection) requiring parenteral anti-infectives and/or hospitalization. Note: An uncomplicated, presumably viral, upper respiratory tract infection (eg, ‘the common cold’) is not an exclusion. 5. Has current alcohol/substance abuse/dependence, or in the Investigator’s opinion, shows evidence of ongoing alcohol/substance abuse/dependence. 6. Has donated or had significant loss of whole blood (480 mL or more) within 30 days, or plasma within 14 days prior to OLE study Day 1. 7. Has a hypersensitivity to M281 or any constituent of the study drug solution. 8. Has had a prior severe drug reaction that included shock or severe hypersensitivity. 9. Has liver impairment with Child-Pugh Class B or C. 10. Has any other medical condition(s) likely to require treatment with oral or parenteral glucocorticosteroids (eg, severe asthma), or has required oral or parenteral glucocorticosteroids in the past 3 months before OLE study Day 1 for conditions other than MG (inhalational, intra-articular, topical or ocular glucocorticosteroids are not exclusionary), or taking any immunosuppressive agents not being used to treat MG. 11. Is receiving a systemic biologic antibody for any concurrent disease. 12. Has a QT interval corrected for heart rate (QTc) at OLE study Day 1 of >450 msec for males or >470 msec for females; or QTc >480 msec in patients with Bundle Branch Block, by the Fridericia formula. 13. Had any of the following abnormal laboratory values based on the safety laboratory tests done at the Day 85 POC Visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase ≥2× upper limit of normal (ULN); or bilirubin ≥1.5×ULN (isolated bilirubin greater than 1.5×ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%, or if there is a prior diagnosis of Gilbert disease without any condition that causes elevation of bilirubin). 14. Had elevated CK ≥2×ULN based on the safety laboratory tests done at the Day 85 POC Visit. Note: If the CK value is ≥2×ULN at the Day 85 POC visit, the value from the Day 113 POC Visit can be used to assess eligibility. If the value from the Day 113 POC Visit is also ≥2×ULN, but <5×ULN, and in the opinion of the investigator the patient has no CK related disease and CK level is believed to be the result of non-pathologic factors, the CK may be repeated once within 28 days and if stable/improved the patient can be enrolled. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and Tolerability of M281 will be evaluated in terms of the Incidence and severity of adverse events (AEs; including serious AEs [SAEs], and AEs of special interest [AESIs]), vital signs, physical examinations, clinical laboratory testing (including chemistry, hematology, coagulation, and urinalysis), electrocardiograms (ECGs), and the Columbia-Suicide Severity Rating Scale (C-SSRS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
AEs are monitored throughout the study Vital signs will be measured immediately prior to the start of each infusion and 30 minutes after the first infusion and second infusions only. Full physical examinations to be performed at study enrollment and end of treatment/early termination, and a focused physical examination at all other site visits clinical laboratory testing (including chemistry, hematology, coagulation, and urinalysis) will be done on day 1, week 2,4,8,12 and every 12 weeks thereafter ECG will be taken immediately prior to the beginning of the infusion and right after the end of the infusion C-SSRS will be administered at the enrollment and then on week 2,4,8,12 and every 12 weeks thereafter |
|
E.5.2 | Secondary end point(s) |
1. Change from baseline in the total Myasthenia Gravis – Activities of Daily Living (MG-ADL) score over time 2. Number of patients with a 2-, 3-, 4-, 5-, 6-, 7-, or ≥8-point improvement in total MG-ADL score over time 3. Change from baseline in total Quantitative Myasthenia Gravis (QMG) score over time 4. Change from baseline in total Revised Myasthenia Gravis Quality of Life – 15 Scale (MG-QoL15r) score over time 5. Change from baseline in Clinical Global Impression of Severity (CGI-S) over time and Clinical Global Impression of Improvement (CGI-I) ratings 6. Change from baseline in Myasthenia Gravis Foundation of America (MGFA) classification over time 7. Incidence of anti-drug antibody (ADA) and neutralizing ADA (nADA) seroconversion over time 8. Total serum immunoglobulin (Ig)G concentrations over time and change from baseline
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and on follow- up visit 2. week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and on follow- up visit 3. week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and follow -up visit 4. week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and on follow up visit 5. baseline, week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and on follow up visit 6. baseline, week 8, and every 24 weeks thereafter and EoT visit 7. week 4 and 8, week 12 and every 12 weeks thereafter, EoT visit and on follow up visit 8. week 2, 4, 8, 12 and every 12 weeks thereafter, EoT visit and on follow up visit
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
tolerability, immunogenicity and biomarkers |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
United States |
Belgium |
Germany |
Italy |
Poland |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
On 09-Dec-2020 the Sponsor made the decision not to recommence the MOM-M281-005 study and to move forward with study closure. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |